Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|December 17, 2025

Gene Therapy Unlocked: Overcome Challenges and Accelerate the Path to Patients

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Key Objectives

  • Learn about the key obstacles gene therapy innovators face, including rapid advancement to first-in-human studies and navigating regulatory approvals.
  • Discover approaches for speeding up process development to achieve efficient, scalable GMP manufacturing for phase 1 clinical trials.
  • Identify essential criteria for selecting the right CDMO partner.

Advanced therapy developers, particularly in the cell and gene therapy space, face intense pressure to balance speed, cost, and GMP compliance as they move from early research into the clinic. An experienced CDMO can mitigate these challenges by offering stage-appropriate support, platform technologies, and flexible manufacturing approaches that accommodate both early academic processes and more mature, transfer-ready programs. Hartmut Tintrup, Executive Director, Commercial Development, FUJIFILM Biotechnologies, highlights how establishing a trusted, financially stable partner with end-to-end capabilities early on can reduce tech transfer risk and enable a smoother path to commercial manufacturing.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.